NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $16.26 -0.48 (-2.87%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$16.07▼$16.9450-Day Range$11.21▼$18.4052-Week Range$3.06▼$18.48Volume3.12 million shsAverage Volume3.05 million shsMarket Capitalization$3.77 billionP/E RatioN/ADividend YieldN/APrice Target$15.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ADMA Biologics alerts: Email Address ADMA Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside4.7% Downside$15.50 Price TargetShort InterestHealthy3.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 4 Articles This WeekInsider TradingSelling Shares$9.13 M Sold Last QuarterProj. Earnings Growth28.57%From $0.49 to $0.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.36 out of 5 starsMedical Sector644th out of 910 stocksBiological Products, Except Diagnostic Industry104th out of 155 stocks 1.6 Analyst's Opinion Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 3 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.89% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently increased by 3.09%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADMA. Previous Next 1.9 News and Social Media Coverage News SentimentADMA Biologics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ADMA Biologics this week, compared to 4 articles on an average week.Search Interest56 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 51% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -76% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,129,891.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ADMA Biologics are expected to grow by 28.57% in the coming year, from $0.49 to $0.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is -813.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is -813.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 20.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About ADMA Biologics Stock (NASDAQ:ADMA)ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More ADMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADMA Stock News HeadlinesAugust 31, 2024 | insidertrades.comInsider Selling: ADMA Biologics, Inc. (NASDAQ:ADMA) COO Sells 24,150 Shares of StockAugust 28, 2024 | insidertrades.comADMA Biologics, Inc. (NASDAQ:ADMA) Director Young Kwon Sells 60,000 SharesSeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 28, 2024 | insidertrades.comADMA Biologics, Inc. (NASDAQ:ADMA) CEO Adam S. Grossman Sells 236,889 SharesSeptember 2, 2024 | americanbankingnews.comADMA Biologics, Inc. (NASDAQ:ADMA) COO Sells $408,135.00 in StockSeptember 2, 2024 | americanbankingnews.comADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells $2,363,589.47 in StockAugust 31, 2024 | yahoo.comPlasma center denies SC woman’s donation because she has HIV. They are wrong, suit saysAugust 30, 2024 | msn.comCramer's Lightning Round: ADMA Biologics is 'a very speculative situation'September 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 29, 2024 | msn.comHere's What Could Help Adma Biologics (ADMA) Maintain Its Recent Price StrengthAugust 29, 2024 | americanbankingnews.comYoung Kwon Sells 60,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) StockAugust 29, 2024 | americanbankingnews.comAdam S. Grossman Sells 236,889 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) StockAugust 28, 2024 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Hits New 52-Week High at $18.58August 17, 2024 | investing.comADMA Biologics repays millions to cut debt by nearly one-fourthAugust 14, 2024 | ca.finance.yahoo.comADMA Sep 2024 13.000 callAugust 14, 2024 | benzinga.comAssessing ADMA Biologics: Insights From 4 Financial AnalystsAugust 14, 2024 | finance.yahoo.comBrokers Are Upgrading Their Views On ADMA Biologics, Inc. (NASDAQ:ADMA) With These New ForecastsAugust 14, 2024 | finance.yahoo.comADMA Biologics Announces Partial Paydown of Revolving Credit FacilitySee More Headlines Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees530Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside-4.7%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio33.18 P/E GrowthN/ANet Income$-28,240,000.00 Net Margins10.53% Pretax Margin11.86% Return on Equity38.79% Return on Assets17.35% Debt Debt-to-Equity Ratio0.74 Current Ratio6.87 Quick Ratio2.80 Sales & Book Value Annual Sales$330.24 million Price / Sales11.41 Cash Flow$0.05 per share Price / Cash Flow340.63 Book Value$0.81 per share Price / Book20.07Miscellaneous Outstanding Shares231,809,000Free Float223,232,000Market Cap$3.77 billion OptionableOptionable Beta0.55 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Adam S. Grossman (Age 47)Co-Founder, President, CEO, Interim CFO & Director Comp: $1.59MDr. Jerrold B. Grossman D.P.S. (Age 76)Ph.D., Co-Founder & Vice Chairman of the Board Comp: $90kMs. Kaitlin Kestenberg (Age 37)COO & Senior VP of Compliance Mr. Drew PantelloVice President of Marketing & Corporate DevelopmentMs. Cindy PetersenExecutive Director of Human ResourcesMr. Skyler BloomSenior Director of Business Development & Corporate StrategyMr. Brad TadeVice President of Financial OperationsMore ExecutivesKey CompetitorsSolid BiosciencesNASDAQ:SLDBLogicBio TherapeuticsNASDAQ:LOGCChampions OncologyNASDAQ:CSBRViatrisNASDAQ:VTRSDr. Reddy's LaboratoriesNYSE:RDYView All CompetitorsInsiders & InstitutionsKaitlin M Kestenberg-MessinaSold 24,150 sharesTotal: $408,135.00 ($16.90/share)Jerrold B GrossmanSold 136,861 sharesTotal: $2.36 M ($17.27/share)Adam S GrossmanSold 236,889 sharesTotal: $4.19 M ($17.69/share)Young KwonSold 60,000 sharesTotal: $1.10 M ($18.26/share)Stonepine Capital Management LLCSold 1,556,882 shares on 8/21/2024Ownership: 0.807%View All Insider TransactionsView All Institutional Transactions ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $4.52 on January 1st, 2024. Since then, ADMA stock has increased by 259.7% and is now trading at $16.26. View the best growth stocks for 2024 here. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) released its earnings results on Thursday, August, 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. The company's revenue for the quarter was up 78.4% on a year-over-year basis. What is Adam S. Grossman's approval rating as ADMA Biologics' CEO? 9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are ADMA Biologics' major shareholders? Top institutional investors of ADMA Biologics include D. E. Shaw & Co. Inc. (2.94%), American Century Companies Inc. (2.61%), Magnetar Financial LLC (1.60%) and Assenagon Asset Management S.A. (1.46%). Insiders that own company stock include Steve Elms, Adam S Grossman, Brian Lenz, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Bryant Fong and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Tilly's (TLYS), Bionano Genomics (BNGO) and Novan (NOVN). This page (NASDAQ:ADMA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
